KM254-ADC

N/A

Report date: 2023/02/23 10:47:36

Base Information

Drug NameKM254-ADC
Drug Alias NameKM254-ADCXZP-KM254
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co LtdBeijing Kangming Bio New Drug Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A